Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 6/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.30 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.30 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.30 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27153696 | 1.00 | ABL1 (0.37) | ABL1EGFRFGFR1SRCFGFR2 | |
| SCHEMBL27138971 | 0.81 | ABL1 (0.33) | ABL1 | |
| SCHEMBL30780124 | 0.81 | ABL1 (0.33) | ABL1 | |
| SCHEMBL27141005 | 0.80 | ABL1 (0.33) | ABL1 | |
| SCHEMBL30780178 | 0.80 | ABL1 (0.33) | ABL1 | |
| SCHEMBL30907413 | 0.80 | ABL1 (0.57) | ABL1 | |
| SCHEMBL30907166 | 0.77 | ABL1 (0.34) | ABL1 | |
| SCHEMBL30780276 | 0.77 | HTT (0.32) | ABL1 | |
| SCHEMBL27139779 | 0.77 | HTT (0.32) | ABL1 | |
| SCHEMBL24666542 | 0.76 | FGFR1 (0.39) | ABL1FGFR1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577546-A1 | NAPHTHYRIDINE COMPOUNDS FOR INHIBITION OF RAF KINASES | Enliven Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| CN-120129682-A | Naphthyridine compounds for inhibition of RAF kinase | 英莱汶公司 | 2025-06-10 | — | — | CN | disclosed |
| WO-2024044713-A1 | NAPHTHYRIDINE COMPOUNDS FOR INHIBITION OF RAF KINASES | ENLIVEN INC. (US) | 2024-02-29 | — | — | WO | disclosed |